Related Experiment Video
Updated: May 13, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?
Joost Besseling1, Julian van Capelleveen, John J P Kastelein
1Department of Vascular Medicine, Academic Medical Centre, Meibergdreef 15, Room F4-139, 1105 AZ, Amsterdam, The Netherlands.
Insights
Low-density lipoprotein cholesterol (LDL-C) is a key cardiovascular disease risk factor. Statins effectively lower LDL-C and CVD risk, with combination therapies considered for patients not reaching target levels.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Low-density lipoprotein cholesterol (LDL-C) is a primary modifiable risk factor for cardiovascular disease (CVD).
- Statins are the primary therapy for lowering LDL-C and reducing CVD risk across most patient populations.
Purpose of the Study:
- To review the rationale behind current LDL-C targets for cardiovascular disease prevention.
- To discuss current and future therapeutic strategies for achieving LDL-C goals.
Main Methods:
- Literature review of guidelines and therapeutic options for LDL-C management.
- Analysis of statin efficacy and role of combination therapies.
Main Results:
- Statins are effective in reducing LDL-C and CVD risk, except in specific conditions like heart failure.
- Combination therapies (ezetimibe, bile acid sequestrants, fibrates) are recommended when LDL-C targets are unmet.
Conclusions:
- Current guidelines establish risk-based LDL-C targets for CVD prevention.
- Achieving LDL-C goals may require statins alone or in combination with other lipid-lowering agents.
Abstract:
It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies.
Related Concept Videos
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipids: Dietary Sources and Requirements
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures
Lipid-Lowering Drugs: Statins and Miscellaneous Agents